|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001675,
umls-concept:C0030705,
umls-concept:C0178602,
umls-concept:C0205179,
umls-concept:C0205314,
umls-concept:C0205390,
umls-concept:C0280100,
umls-concept:C0679622,
umls-concept:C1451033,
umls-concept:C1879762,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-28
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of the 24-h continuous intravenous (CIV) infusion of MK-0457, a novel pan-Aurora kinase inhibitor, in patients with advanced solid tumors and to determine the bioavailability of an oral dose of 100 mg MK-0457.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
pubmed-author:ClarkJasonJ,
pubmed-author:FlahertyKeith TKT,
pubmed-author:FreedmanSteven JSJ,
pubmed-author:HewittMaureenM,
pubmed-author:LeightonAnn MarieAM,
pubmed-author:LiuGlennG,
pubmed-author:O'DwyerPeter JPJ,
pubmed-author:ScottBoyd BBB,
pubmed-author:TraynorAnne MAM,
pubmed-author:WatsonPatricia APA,
pubmed-author:WildingGeorgeG,
pubmed-author:ZhaoBaitengB
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
305-14
|
|
pubmed:dateRevised |
2011-7-11
|
|
pubmed:meshHeading |
pubmed-meshheading:20386909-Administration, Oral,
pubmed-meshheading:20386909-Adult,
pubmed-meshheading:20386909-Aged,
pubmed-meshheading:20386909-Aged, 80 and over,
pubmed-meshheading:20386909-Area Under Curve,
pubmed-meshheading:20386909-Biological Availability,
pubmed-meshheading:20386909-Female,
pubmed-meshheading:20386909-Hematologic Diseases,
pubmed-meshheading:20386909-Humans,
pubmed-meshheading:20386909-Infusions, Intravenous,
pubmed-meshheading:20386909-Male,
pubmed-meshheading:20386909-Maximum Tolerated Dose,
pubmed-meshheading:20386909-Middle Aged,
pubmed-meshheading:20386909-Neoplasms,
pubmed-meshheading:20386909-Piperazines,
pubmed-meshheading:20386909-Protein-Serine-Threonine Kinases,
pubmed-meshheading:20386909-Treatment Outcome,
pubmed-meshheading:20386909-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
|
|
pubmed:affiliation |
University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 3103 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA. amt@medicine.wisc.edu
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase I
|
